South America Neurodegenerative Disease Market

ID: MRFR/LS/50857-HCR
200 Pages
Vikita Thakur
Last Updated: April 24, 2026
South America Neurodegenerative Disease Market Research Report By Disease Type (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Huntington's Disease), By Diagnosis Method (Neurological Examination, Imaging Techniques, Cerebrospinal Fluid Analysis, Electrophysiological Tests), By Treatment Type (Medication, Therapy, Rehabilitation, Surgical Interventions), By Route of Administration (Oral, Injectable, Intravenous, Transdermal) and By Regional (Brazil, Mexico, Argentina, Rest of South America) -Forecast to 2035
South America Neurodegenerative Disease Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)7.71%
2024 Market Size$ 3,400 Million
2025 Market Size$ 3,662.14 Million
2035 Market Size$ 7,700 Million
Key Players
Biogen
Eli Lilly
Roche
Novartis
AstraZeneca
Merck & Co
Trends
  • Rising Prevalence of Neurodegenerative Disorders
  • Advancements in Research and Technology
  • Evolving Regulatory Frameworks
Opportunities
  • Aging Population in South America
  • Increased Awareness and Education
  • Investment in Healthcare Infrastructure
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Disease Type (USD Billion)
      1. 4.1.1 Alzheimer's Disease
      2. 4.1.2 Parkinson's Disease
      3. 4.1.3 Huntington's Disease
      4. 4.1.4 Amyotrophic Lateral Sclerosis
      5. 4.1.5 Multiple Sclerosis
    2. 4.2 Healthcare, BY Treatment Type (USD Billion)
      1. 4.2.1 Medication
      2. 4.2.2 Physical Therapy
      3. 4.2.3 Occupational Therapy
      4. 4.2.4 Speech Therapy
      5. 4.2.5 Supportive Care
    3. 4.3 Healthcare, BY Patient Demographics (USD Billion)
      1. 4.3.1 Age Group
      2. 4.3.2 Gender
      3. 4.3.3 Socioeconomic Status
      4. 4.3.4 Geographic Distribution
      5. 4.3.5 Ethnicity
    4. 4.4 Healthcare, BY Stage of Disease (USD Billion)
      1. 4.4.1 Early Stage
      2. 4.4.2 Moderate Stage
      3. 4.4.3 Advanced Stage
      4. 4.4.4 Preclinical Stage
      5. 4.4.5 Relapse Stage
    5. 4.5 Healthcare, BY Healthcare Setting (USD Billion)
      1. 4.5.1 Hospitals
      2. 4.5.2 Outpatient Clinics
      3. 4.5.3 Home Care
      4. 4.5.4 Rehabilitation Centers
      5. 4.5.5 Long-term Care Facilities
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Roche (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Novartis (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Bristol-Myers Squibb (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Eli Lilly and Company (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Biogen (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Sanofi (FR)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Merck & Co. (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Amgen (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 AstraZeneca (GB)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 SOUTH AMERICA MARKET ANALYSIS BY DISEASE TYPE
    3. 6.3 SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
    4. 6.4 SOUTH AMERICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    5. 6.5 SOUTH AMERICA MARKET ANALYSIS BY STAGE OF DISEASE
    6. 6.6 SOUTH AMERICA MARKET ANALYSIS BY HEALTHCARE SETTING
    7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF HEALTHCARE
    10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
    13. 6.13 HEALTHCARE, BY DISEASE TYPE, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY DISEASE TYPE, 2024 TO 2035 (USD Billion)
    15. 6.15 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
    17. 6.17 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
    18. 6.18 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion)
    19. 6.19 HEALTHCARE, BY STAGE OF DISEASE, 2024 (% SHARE)
    20. 6.20 HEALTHCARE, BY STAGE OF DISEASE, 2024 TO 2035 (USD Billion)
    21. 6.21 HEALTHCARE, BY HEALTHCARE SETTING, 2024 (% SHARE)
    22. 6.22 HEALTHCARE, BY HEALTHCARE SETTING, 2024 TO 2035 (USD Billion)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DISEASE TYPE, 2026-2035 (USD Billion)
      2. 7.2.2 BY TREATMENT TYPE, 2026-2035 (USD Billion)
      3. 7.2.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Billion)
      4. 7.2.4 BY STAGE OF DISEASE, 2026-2035 (USD Billion)
      5. 7.2.5 BY HEALTHCARE SETTING, 2026-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

South America South America Neurodegenerative Disease Market Segmentation

South America Neurodegenerative Disease Market By Disease Type (USD Billion, 2022-2035)

  • Alzheimer's Disease
  • Parkinson's Disease
  • Huntington's Disease
  • Amyotrophic Lateral Sclerosis
  • Multiple Sclerosis

South America Neurodegenerative Disease Market By Treatment Type (USD Billion, 2022-2035)

  • Medication
  • Physical Therapy
  • Occupational Therapy
  • Speech Therapy
  • Supportive Care

South America Neurodegenerative Disease Market By Patient Demographics (USD Billion, 2022-2035)

  • Age Group
  • Gender
  • Socioeconomic Status
  • Geographic Distribution
  • Ethnicity

South America Neurodegenerative Disease Market By Stage of Disease (USD Billion, 2022-2035)

  • Early Stage
  • Moderate Stage
  • Advanced Stage
  • Preclinical Stage
  • Relapse Stage

South America Neurodegenerative Disease Market By South America Neurodegenerative Disease Market Setting (USD Billion, 2022-2035)

  • Hospitals
  • Outpatient Clinics
  • Home Care
  • Rehabilitation Centers
  • Long-term Care Facilities

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.